Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of tuberculosis are also disclosed.
Drawings
Claims15
A method for producing an immune response to Mycobacterium tuberculosis in a subject, comprising
administering to the subject a therapeutically effective amount of an isolated polypeptide, wherein the isolated polypeptide comprises:
the amino acid sequence set forth as SEQ ID NO:
10,
thereby inducing an immune response to Mycobacterium tuberculosis.
1 more element
A method for treating a subject infected with Mycobacterium tuberculosis, comprising administering to the subject a therapeutically effective amount of an isolated polypeptide, wherein the isolated polypeptide comprises:
the amino acid sequence set forth as SEQ ID NO:
10,
thereby treating the subject infected with Mycobacterium tuberculosis.
12/282,865Filed 14 Mar 2007 · us provisional application
Priority
14 Mar 2006
Published
US 2009/0124549 A114 May 2009
Granted
30 Nov 2010
Term ends
14 Mar 2027Estimated · howhide20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.
About 5 months of term left · ends 14 Mar 2027 (estimated)
Priority14 Mar 2006
Filed14 Mar 2007
Published14 May 2009
Granted30 Nov 2010
Today12 Oct 2026
Term ends14 Mar 2027
Priority14 Mar 2006
Granted30 Nov 2010
Term ends14 Mar 2027
Priority claimedParent application 60/782,364
Application filedUS 12/282,865
Assigned to Oregon Health & Science Universityassignment of assignor's interest
Assigned to The Government of the United States of America, Dba the Department of Veterans Affairsassignment of assignor's interest
Assigned to National Institutes of Health (Nih), U.S. Dept. of Health and Human Services (Dhhs), U.S. Governmentexecutive order 9424, confirmatory license
PublishedUS 2009/0124549 A1
GrantedUS 7,842,299 B2
TodayWithin its term
Term endsEstimated
Description23,873 words
Summary852 words
#This application relates to the field of immunology, more specifically to methods for the production of an immune response to tuberculosis antigens.
#Mycobacteria are a genus of aerobic intracellular bacterial organisms that, upon infection of a host, survive within endosomal compartments of monocytes and macrophages. Human mycobacterial diseases include tuberculosis (caused by M. tuberculosis), leprosy (caused by M. leprae), Bairnsdale ulcers (caused by M. ulcerans), and various infections caused by M. marinum, M. kansasii, M. scrofulaceum, M. szulgai, M. xenopi, M. fortuitum, M. chelonei, M. haemophilum and M. intracelullare (see Wolinsky, E., Chapter 37 in Microbiology: Including Immunology and Molecular Genetics, 3rd Ed., Harper & Row, Philadelphia, 1980).
#One third of the world's population harbors M. tuberculosis and is at risk for developing tuberculosis (TB). In immunocompromised patients, tuberculosis is increasing at a nearly logarithmic rate, and multidrug resistant strains are appearing. In addition, Mycobacterial strains which were previously considered to be nonpathogenic strains (e.g., M. avium) have now become major killers of immunosuppressed AIDS patients. Moreover, current Mycobacterial vaccines are either inadequate (such as the BCG vaccine for M. tuberculosis) or unavailable (such as for M. leprae) (Kaufmann, S., Microbiol. Sci. 4:324-328-1987; U.S. Congress, Office of Technology Assessment, The Continuing Challenge of Tuberculosis, pp. 62-67, OTA-H-574, U.S. Government Printing Office, Washington, D.C., 1993).
Brief description of the drawings7 figures
#FIG. 1 is two graphs showing the determination of human effector cell frequencies ex vivo using the IFN-γ ELISPOT assay. Magnetic bead-purified CD8+ T cells were cultured with DC (20,000/well) either infected with Mtb (H37Rv, MOI =50) or pulsed with peptide pool representing CFP10 (5 μg/ml each peptide; 15-mers overlap 11 aa) in an IFN-γ ELISPOT assay. Each responding T cell population was tested in duplicate at four different cell concentrations. To determine the effector cell frequency of antigen-specific T cells, the average number of spots per well for each duplicate was plotted against the number of responder cells per well. Linear regression analysis was used to determine the slope of the line, which represents the frequency of antigen-specific T cells. The assay was considered positive (reflecting the presence of a primed T cell response), if the binomial probability for the number of spots was significantly different by experimental and control assays.
#FIG. 2 is a set of graphs showing ex vivo CD8+ T cell-frequencies to Mtb antigens are associated with Mtb infection. As described above (see FIG. 1), to determine ex vivo CD8+ T cell frequencies, autologous DC either infected with Mtb or pulsed with cognate peptide pools were incubated with CD8+ T cells in an IFN-γ ELISPOT assay. Subjects without evidence for Mtb infection, those with LTBI, and those with active TB (culture confirmed pulmonary tuberculosis) were evaluated. “Mtb Infected” includes those with latent tuberculosis (TB) infection and active tuberculosis. P values are noted where P=<0.05 (Wilcoxon/Kiuskal-Wallis).
#FIGS. 3a to 3d are a set of digital images showing the definition of Antigenic Specificity and HLA-Restriction (the characterization of T cell clone D466 D6). For the results shown in FIGS. 3a-3c, to identify the antigen and minimal epitope recognized by T cell clone, D466 D6, T-cells (5000 cells/well) were incubated with autologous LCL (20,000/well) and 5 μg/ml of antigen. IFN-γ was assessed by ELISPOT after eighteen hours of co-culture. For the results presented in FIG. 3a, antigens consisted of peptide pools representing known CD4+ antigens, made up of 15 amino acid (aa) peptides overlapping by 11 aa. For the results presented in FIG. 3b, antigens consisted of individual 15 aa CFP10 peptides that together constitute the peptide pool. For the results presented in FIG. 3c, antigens consisted of individual nested CFP101-15 peptide's (10 aa, 9 aa or 8 aa), used to further map the epitope. For the results presented in FIG. 3d, the restricting allele was identified using LCL (20,000/well) expressing HLA alleles matching D466 at one or two alleles, pulsed with CFP102-10 (5 μg/ml) as APC. After 2 hours, cells were washed and incubated with T-cells (500 cells/well) in an IFN-γ ELISPOT assay.
Detailed description22,324 words
#The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. In the accompanying sequence listing:
#SEQ ID NOs: 1-12 are the amino acid sequence of Mtb polypeptides.
#SEQ ID NOs: 13-14 are amino acids of Mtb peptides.